| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fesoterodine (Toviaz®) |
| Formulation | 4 mg and 8 mg prolonged-release tablet |
| Reference number | 146 |
| Indication | Treatment of the symptoms (increased urinary frequency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome |
| Company | Pfizer Ltd |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 05/02/2008 |